InvestSMART

Cleo Diagnostics Ltd (ASX:COV)

ALERT: Price-sensitive ASX Announcement for COV
Current share price for COV : $0.320 -0.305 (-48.80%)+
Announcement
Release
28 Apr 2026 8:26AM
Price at Release
$0.625
Full Release
download
Summary
Cleo Diagnostics Ltd has embarked on a significant milestone with the commencement of a staged manufacturing program for its ovarian cancer test kits, utilizing Bio-Techne's Ella™ platform. This marks a pivotal transition from clinical sample collection to analytical validation (AV) and clinical sample testing, essential steps for their planned FDA 510(k) submission. The collaboration with Bio-Techne aims to ensure high sensitivity, precision, and reproducibility of the test kits, reducing technical and manufacturing risks. This development is foundational as it supports the progression through AV by generating necessary data for the FDA submission, with the ultimate goal of addressing a critical need for early ovarian cancer detection.
Key Points
  • Cleo Diagnostics Ltd begins staged manufacturing of ovarian cancer test kits with Bio-Techne.
  • The program supports CLEO's analytical validation and FDA submission efforts.
  • The Ella™ platform is utilized for delivering CLEO's biomarker panel.
  • The staged approach reduces technical and manufacturing risks.
  • The program is foundational for generating necessary data for FDA 510(k) submission.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.